181 related articles for article (PubMed ID: 15346837)
21. A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images.
Venkataraman R; Belardinelli L; Blackburn B; Heo J; Iskandrian AE
JACC Cardiovasc Imaging; 2009 Nov; 2(11):1301-9. PubMed ID: 19909934
[TBL] [Abstract][Full Text] [Related]
22. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion.
Wang P; Fraser H; Lloyd SG; McVeigh JJ; Belardinelli L; Chatham JC
J Pharmacol Exp Ther; 2007 Apr; 321(1):213-20. PubMed ID: 17202401
[TBL] [Abstract][Full Text] [Related]
23. Chronic angina: new medical options for treatment.
McCullough PA
Rev Cardiovasc Med; 2005; 6(3):152-61. PubMed ID: 16195688
[TBL] [Abstract][Full Text] [Related]
24. Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36).
Mega JL; Hochman JS; Scirica BM; Murphy SA; Sloan S; McCabe CH; Merlini P; Morrow DA
Circulation; 2010 Apr; 121(16):1809-17. PubMed ID: 20385930
[TBL] [Abstract][Full Text] [Related]
25. Modification of myocardial substrate use as a therapy for heart failure.
Abozguia K; Clarke K; Lee L; Frenneaux M
Nat Clin Pract Cardiovasc Med; 2006 Sep; 3(9):490-8. PubMed ID: 16932766
[TBL] [Abstract][Full Text] [Related]
26. Metabolic agents in the management of diabetic coronary patients: a new era.
Marazzi G; Volterrani M; Rosano GM
Int J Cardiol; 2008 Jun; 127(1):124-5. PubMed ID: 18199501
[TBL] [Abstract][Full Text] [Related]
27. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism.
Lopaschuk GD
Am J Cardiol; 1998 Sep; 82(5A):14K-17K. PubMed ID: 9737481
[TBL] [Abstract][Full Text] [Related]
28. Management of myocardial ischemia. Is ranolazine needed? For all or some patients with myocardial ischemia?
Cocco G
Expert Opin Pharmacother; 2012 Dec; 13(17):2429-32. PubMed ID: 23121536
[TBL] [Abstract][Full Text] [Related]
29. Modulation of myocardial metabolism: an emerging therapeutic principle.
Horowitz JD; Chirkov YY; Kennedy JA; Sverdlov AL
Curr Opin Cardiol; 2010 Jul; 25(4):329-34. PubMed ID: 20535068
[TBL] [Abstract][Full Text] [Related]
30. Non-haemodynamic anti-anginal agents in the management of patients with stable coronary artery disease and diabetes: A review of the evidence.
Ambrosio G; Tamargo J; Grant PJ
Diab Vasc Dis Res; 2016 Mar; 13(2):98-112. PubMed ID: 26873904
[TBL] [Abstract][Full Text] [Related]
31. [Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism].
Lopaschuk GD
Presse Med; 1998 Dec; 27(39):2100-4. PubMed ID: 9893703
[TBL] [Abstract][Full Text] [Related]
32. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography.
Mody FV; Singh BN; Mohiuddin IH; Coyle KB; Buxton DB; Hansen HW; Sumida R; Schelbert HR
Am J Cardiol; 1998 Sep; 82(5A):42K-49K. PubMed ID: 9737485
[TBL] [Abstract][Full Text] [Related]
33. Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmias.
Stone PH
Cardiol Clin; 2008 Nov; 26(4):603-14. PubMed ID: 18929234
[TBL] [Abstract][Full Text] [Related]
34. Influence of trimetazidine and ranolazine on endothelial function in patients with ischemic heart disease.
Rehberger-Likozar A; Šebeštjen M
Coron Artery Dis; 2015 Dec; 26(8):651-6. PubMed ID: 26049922
[TBL] [Abstract][Full Text] [Related]
35. The electrophysiological properties of ranolazine: a metabolic anti-ischemic drug or an energy-efficient antiarrhythmic agent?
Cingolani E; Lepor NE; Singh BN
Rev Cardiovasc Med; 2011; 12(3):136-42. PubMed ID: 22080924
[TBL] [Abstract][Full Text] [Related]
36. Partial fatty acid oxidation (pFOX) inhibition: a new therapy for chronic stable angina.
Conti CR
Clin Cardiol; 2003 Apr; 26(4):161-2. PubMed ID: 12708620
[TBL] [Abstract][Full Text] [Related]
37. Modulation of myocardial energetics: An important category of agents in the multimodal treatment of coronary artery disease and heart failure.
Dalal JJ; Mishra S
Indian Heart J; 2017; 69(3):393-401. PubMed ID: 28648439
[TBL] [Abstract][Full Text] [Related]
38. Metabolic modulation: a new therapeutic target in treatment of heart failure.
Palaniswamy C; Mellana WM; Selvaraj DR; Mohan D
Am J Ther; 2011 Nov; 18(6):e197-201. PubMed ID: 20393344
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial.
Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Skene A; McCabe CH; Braunwald E;
Am Heart J; 2006 Jun; 151(6):1186.e1-9. PubMed ID: 16781216
[TBL] [Abstract][Full Text] [Related]
40. [Mechanisms of myocardial cell protection from ischemia/reperfusion injury and potential clinical implications].
Lamendola P; Di Monaco A; Barone L; Pisanello C; Lanza GA; Crea F
G Ital Cardiol (Rome); 2009 Jan; 10(1):28-36. PubMed ID: 19292017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
